Effects of sacubitril-valsartan in the treatment of chronic heart failure patients with end-stage renal disease undergoing dialysis.

ABSTRACT:

Background

The data on the effects of the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril-valsartan (LCZ696) in chronic heart failure (CHF) patients with end-stage renal disease (ESRD) requiring dialysis are lacking. This study assessed the efficacy and safety of LCZ696 in CHF patients with ESRD on dialysis.

Hypothesis

LCZ696 treatment can reduce rehospitalization rate for HF, delay the occurrence of rehospitalization for HF, and prolong the survival time.

Methods

We retrospectively analyzed the clinical data of CHF patients with ESRD on dialysis who were admitted to the Second Hospital of Tianjin Medical University from August 2019 to October 2021.

Results

Sixty-five patients had primary outcome during the follow-up. The incidence of rehospitalizat

SUBMITTER: Liu X 

PROVIDER: S-EPMC10436793 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature